Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of HLX43 plus serplulimab in advanced or metastatic solid tumors
CTR20250349Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX43, serplulimab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), sponsored by HyBioPharma. Started Apr 2025; status: active.
02
Drugs
HLX43serplulimab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20250349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250349.